Citigroup
KYTX icon

Citigroup’s Kyverna Therapeutics KYTX Stock Holding History

Citigroup’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Sell
20,858
-21,402
-51% -$190K ﹤0.01% 4385
2026
Q1 		$365K Buy
42,260
+29,963
+244% +$250K ﹤0.01% 3718
2025
Q4 		$116K Buy
12,297
+8,978
+271% +$66.7K ﹤0.01% 4263
2025
Q3 		$19.9K Sell
3,319
-12,513
-79% -$50K ﹤0.01% 4821
2025
Q2 		$48.6K Sell
15,832
-3,321
-17% -$8.21K ﹤0.01% 4771
2025
Q1 		$37K Sell
19,153
-1,172
-6% -$3.46K ﹤0.01% 4961
2024
Q4 		$76K Buy
20,325
+6,831
+51% +$32.7K ﹤0.01% 4950
2024
Q3 		$66K Buy
13,494
+8,318
+161% +$64.1K ﹤0.01% 4929
2024
Q2 		$38.8K Sell
5,176
-54,490
-91% -$832K ﹤0.01% 4723
2024
Q1 		$1.48M Buy
+59,666
New +$1.66M ﹤0.01% 2698

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Citigroup's KYTX Position: Q2 2026 in Review

Citigroup reduced its Kyverna Therapeutics (KYTX) stake by 51% in Q2 2026, selling an estimated $190K and leaving 20,858 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #4385.

Citigroup first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.48M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Citigroup held 20,858 shares of Kyverna Therapeutics worth $186K as of Q2 2026.
  • Citigroup sold 21,402 Kyverna Therapeutics shares in Q2 2026, an estimated $190K.
  • Kyverna Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4385 holding.
  • Citigroup first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Citigroup's Kyverna Therapeutics position peaked at $1.48M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.